Table 1: Patient characteristics.
|
|
|
|
No. (%) |
||
|
Factors |
|
No. (%) |
2D-RT |
3D-CRT |
IMRT |
|
Median age (years) |
|
|
71 (56-85) |
73* (55-85) |
72 (57-80) |
|
Median RT dose |
66 – 68 Gy |
10 (15) |
0 |
7 (33) |
3 (23) |
|
|
72 – 74 Gy |
39 (57) |
34 (100) |
23(14) |
2 (15) |
|
|
76 – 78 Gy |
19 (28) |
0 |
11 (53) |
8 (62) |
|
T Stage |
T1 / T2 |
57 (84) |
31 (91) |
17 (81) |
9 (69) |
|
|
T3 / T4 |
5 (7) |
1 (3) |
3 (14) |
1 (8) |
|
|
- |
6 (9) |
2 (6) |
1 (5) |
3 (23) |
|
N Stage |
N0 |
30 (44) |
13 (38) |
11 (52) |
6 (46) |
|
|
N1 |
3 (4) |
2 (6) |
1 (5) |
0 |
|
|
NX |
29 (43) |
17 (50) |
8 (38) |
4 (3) |
|
|
- |
6 (9) |
2 (6) |
1 (5) |
3 (23) |
|
Gleason score |
2 – 6 |
21 (31) |
12 (35) |
4 (19) |
5 (38) |
|
|
7 – 10 |
47 (69) |
22 (65) |
17 (81) |
8 (62) |
|
Treatment |
RP |
15 (22) |
3 (20) |
7 (47) |
5 (33) |
|
|
HT |
46 (68) |
26 (57) |
14 (30) |
6 (13) |
2D-RT, conventional radiotherapy; 3D-CRT, conformal radiotherapy; IMRT, intensity-modulate radiotherapy; RT, radiotherapy; RP, radical prostatectomy; HT, hormonal therapy; -, not informed.